14 research outputs found
Diffusie van gezondheidsbevorderende interventies: beschrijving van invoeringsproces- en strategieën
Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice
Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma
Background: Truncated tissue factor (tTF) retargeted by NGR-peptides to aminopeptidase N (CD13) in tumor vasculature is effective in experimental tumor therapy. tTF-NGR induces tumor growth inhibition in a variety of human tumor xenografts of different histology. To improve on the therapeutic efficacy we have combined tTF-NGR with radiotherapy. Methods: Serum-stimulated human umbilical vein endothelial cells (HUVEC) and human HT1080 sarcoma cells were irradiated in vitro, and upregulated early-apoptotic phosphatidylserine (PS) on the cell surface was measured by standard flow cytometry. Increase of cellular procoagulant function in relation to irradiation and PS cell surface concentration was measured in a tTF-NGR-dependent Factor X activation assay. In vivo experiments with CD-1 athymic mice bearing human HT1080 sarcoma xenotransplants were performed to test the systemic therapeutic effects of tTF-NGR on tumor growth alone or in combination with regional tumor ionizing radiotherapy. Results: As shown by flow cytometry with HUVEC and HT1080 sarcoma cells in vitro, irradiation with 4 and 6 Gy in the process of apoptosis induced upregulation of PS presence on the outer surface of both cell types. Proapoptotic HUVEC and HT1080 cells both showed significantly higher procoagulant efficacy on the basis of equimolar concentrations of tTF-NGR as measured by FX activation. This effect can be reverted by masking of PS with Annexin V. HT1080 human sarcoma xenografted tumors showed shrinkage induced by combined regional radiotherapy and systemic tTF-NGR as compared to growth inhibition achieved by either of the treatment modalities alone. Conclusions: Irradiation renders tumor and tumor vascular cells procoagulant by PS upregulation on their outer surface and radiotherapy can significantly improve the therapeutic antitumor efficacy of tTF-NGR in the xenograft model used. This synergistic effect will influence design of future clinical combination studies
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group
Importance of individual activated protein C cleavage site regions in coagulation Factor V for Factor Va inactivation and for Factor Xa activation
Adjuvant chemotherapyâRadiotherapyâChemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases
Adjuvant therapy of local soft tissue sarcomas (STS) after wide surgical excision still is a topic under controversial scientific debate. In this single center report we have offered an adjuvant âsandwichâ therapy protocol consisting of 4 cycles of doxorubicin (75 mg/m2 i.v. over 1 h on day 1) followed by ifosfamide (5 g/m2 i.v. over 24 h starting on day 1) and local radiotherapy scheduled between chemotherapy cycles 2 and 3 to 104 consecutive patients after wide surgical excision (R0) of histologically proven high-grade STS. After a mean follow-up of 39 months (range 5â194 months) relapse free survival (RFS) at 2 and 5 years was 68.1% (95% CI, 58.5â77.7%) and 61.2% (95% CI, 50.4â71.6%). When analyzing the 82 STS cases of the extremities only 2- and 5-year RFS was 74.0% (95% CI, 64.0â84.0%) and 65.3% (95% CI, 53.7â76.9%). By intent-to-treat analysis, the overall survival (OS) at 2 years was 87.3% (95% CI, 80.5â94.1%) and 75.6% (95% CI, 65.2â86.0%) at 5 years, while OS for STS of the extremities only cohort was 90.5% (95% CI, 83.7â97.3%) and 79.0% (95% CI, 68.4â89.6%), respectively. Tolerability of the treatment was good. This analysis demonstrates the feasibility of adjuvant chemoradiotherapy and reflects the results of the long lasting intensive multidisciplinary team approach at our âhigh-volumeâ sarcoma center. The long-term survival in our patients is among the highest reported and the low local and distant recurrence rate in high-risk STS is at least comparable to the published data
Supplementary Material for: Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis
<p>Within this retrospective single-center study, we analyzed the
survival of 320 multiple myeloma (MM) patients receiving melphalan
high-dose chemotherapy (HDCT) and either single (<i>n</i> = 286) or tandem (<i>n</i>
= 34) autologous stem cell transplantation (ASCT) from 1996 to 2012.
Additionally, the impact of novel induction regimens was assessed.
Median follow-up was 67 months, median overall survival (OS) 62 months,
median progression-free survival (PFS) 33 months (95% CI 27-39), and
treatment-related death (TRD) 3%. Multivariate analysis revealed age â„60
years (<i>p = </i>0.03) and stage 3 according to the International Staging System (<i>p = </i>0.006)
as adverse risk factors regarding PFS. Median OS was significantly
better in newly diagnosed MM patients receiving induction therapy with
novel agents, e.g., bortezomib, thalidomide, or lenalidomide, compared
with a traditional regimen (69 vs. 58 months; <i>p = </i>0.01). More
patients achieved at least a very good partial remission in the period
from 2005 to 2012 than from 1996 to 2004 (65 vs. 30%; <i>p</i> < 0.001), with a longer median OS in the later period (71 vs. 52 months, <i>p</i>
= 0.027). In conclusion, our analysis confirms HDCT-ASCT as an
effective therapeutic strategy in an unselected large myeloma patient
cohort with a low TRD rate and improved prognosis due to novel induction
strategies.</p
The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.
Calcitonin receptor-like (CALCRL) is a G-protein-coupled neuropeptide receptor involved in the regulation of blood pressure, angiogenesis, cell proliferation, and apoptosis, and is currently emerging as a novel target for the treatment of migraine. This study characterizes the role of CALCRL in acute myeloid leukemia (AML). We analyzed CALCRL expression in collectively more than 1500 well-characterized AML patients from five international cohorts (AMLCG, HOVON, TCGA, Leucegene, and UKM) and evaluated associations with survival. In the AMLCG analytic cohort, increasing transcript levels of CALCRL were associated with decreasing complete remission rates (71.5%, 53.7%, 49.6% for low, intermediate, high CALCRL expression), 5-year overall (43.1%, 26.2%, 7.1%), and event-free survival (29.9%, 15.8%, 4.7%) (all P < 0.001). CALCRL levels remained associated with all endpoints on multivariable regression analyses. The prognostic impact was confirmed in all validation sets. Genes highly expressed in CALCRLhigh AML were significantly enriched in leukemic stem cell signatures and CALCRL levels were positively linked to the engraftment capacity of primary patient samples in immunocompromised mice. CRISPR- Cas9-mediated knockout of CALCRL significantly impaired colony formation in human myeloid leukemia cell lines. Overall, our study demonstrates that CALCRL predicts outcome beyond existing risk factors and is a potential therapeutic target in AML